Webinars

Extend your knowledge with exclusive access to thought leaders.

Capital Markets Preview: Patience, optimism, resilience, plus data

RECORDED | ON-DEMAND

Thursday, June 20, 2024 | 11AM ET

Presented by BioCentury and Oppenheimer

After the worst downturn in biotech history, are there finally signs of optimism heading into the second half?

Join BioCentury and Oppenheimer & Co. for an in-depth discussion with investors and pharma dealmakers about where the biotech market is headed.

Interested in sponsoring a webinar? Contact Eric Pierce.

Capital Markets Preview: Patience, optimism, resilience, plus data

PRESENTED BY:

Explore Our Webinars On-Demand

WebsiteFinance

Creating high value biotechs: the tier jumpers

A panel of industry thought leaders discuss the ingredients for creating and growing biotechs to the highest market cap tier, and how the fundamentals will play out in the industry following the market reset. Topics include: What are the keys to building sustainable high-value biotechs? What is required for biotechs to jump market cap tier? And what are the principal challenges faced by today’s CEOs? A BioCentury On-Demand Webinar.

EventPolitics, Policy & LawMar 30, 2023

Navigating the IRA: What biopharma need to know

The drug price-setting provisions of the Inflation Reduction Act (IRA) will reconfigure the commercial landscape in the U.S., forcing biopharma companies and their investors to develop new strategies for R&D and business success.

EventProduct DevelopmentJun 14, 2022

Data-driven Covariate Adjustment to De-risk and Accelerate Clinical Trials

Learn how using data-driven approaches to guide covariate adjustment – controlling for baseline patient variables to better estimate treatment effects – can improve clinical trials.

EventProduct DevelopmentMar 22, 2022

Unlocking cancer patient data for AI-accelerated drug discovery

Industry KOL's discussed the current state of AI in oncology, and how building research networks in a privacy-preserving way is key for unlocking insights from the vast amount of patient data in hospitals and research centers to accelerate drug discovery.

EventPolitics, Policy & LawApr 1, 2021

BIO 3.0: How the Biotech Trade Association is Reinventing Itself for a Changing Political Environment

Michelle McMurry-Heath assumed leadership of the Biotechnology Innovation Organization in May, 2020, when the economy had shut down. No one knew that over the next 10 months, almost 3 million people around the world would die from COVID, or that stunningly effective vaccines pioneered by biotechs would be developed in record time.

EventProduct DevelopmentJul 8, 2021

COVID-19: Reimaging Biotech in 2021

As global biopharma leaders make contingency plans and build scenarios for a COVID-19 world, many are left to wonder: What will 2021 look like?

EventProduct DevelopmentNov 3, 2021

Accelerating Drug Development through RWE in China

Industry KOLs discussed findings from a recent survey from BioCentury and Happy Life Tech on Real World Evidence (RWE) and opportunities for Western biopharmas to accelerate drug development via RWE studies in China.

EventProduct DevelopmentMay 27, 2020

What Comes Next? Strategies for COVID-19 Vaccine Development

In a recent webinar, BioCentury, BioKatalyst and Lonza brought together industry and policy leaders to discuss how to accelerate COVID-19 vaccine development.

EventProduct DevelopmentMay 21, 2020

Adaptive Response to Covid-19: b cells, t cells and vaccine design

With over 100 COVID-19 vaccine candidates in development and 7+ in the clinic, the key question becomes which antigen targets and vaccine modalities will induce the most protective forms of immunity.

EventProduct DevelopmentAug 5, 2020

Good Test Hunting: The Road to Testing that Enables Reopening

Testing has been deemed fundamental to quashing the spread of COVID-19 and bringing back normal activities like gathering indoors. But even as hundreds of tests come onto the market, ensuring COVID-19 testing is broadly accessible, reliable and actionable remains a challenge.

EventFinanceAug 12, 2020

Dealmaking in the COVID-19 Environment

From deal selection and strategies, to timing and due diligence, global biopharma leaders are considering how to adapt their dealmaking to the COVID-19 era. Following the discussion, BioCentury and PJT convene a special panel of biotech CEOs to discuss the survey, and the outlook for biotech transactions.

WebsiteFinance

Capital Markets Preview: Patience, optimism, resilience, plus data

After the worst downturn in biotech history, are there finally signs of optimism heading into the second half? A BioCentury On-Demand Webinar.

Engage

Sponsor a Webinar

Sponsoring a BioCentury Webinar is a unique opportunity to showcase your organization's skills and competency to the biopharma C-suite.

Become a Sponsor

Engage

Sponsor a Conference

Join the many companies that support BioCentury-BayHelix East-West Biopharma Summit and Bio€quity Europe.

Become a Sponsor